Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human FCGR3A / CD16a (V176) Protein, His-Tag, 100µg  

Recombinant Human FCGR3A / CD16a (V176) Protein, His-Tag, 100µg

Recombinant Human FCGR3A / CD16a (V176) Protein, produced in human 293 cells, Gly 17 - Gln 208, His Tag, SPR verified

Synonym
recombinant, human, protein, FCGR3A, CD16A, FCG3, FCGR3, IGFR3

More details

CD8-H52H4-100

Availability: within 7 days

336,00 €

Background
CD16a antigen also known as Low affinity immunoglobulin gamma Fc region receptor III-A, Fc-gamma RIII-alpha. In humans, CD16 has been identified as Fc receptors FcγRIIIa (CD16a) and FcγRIIIb (CD16b), encoded by two different highly homologous genes in a cell type-specific manner. CD16b is a low-affinity, GPI-linked receptor expressed by neutrophils and eosinophils, whereas CD16a is an intermediate affinity polypeptide-anchored transmembrane glycoprotein expressed natural killer cells, macrophages, subpopulation of T-cells, immature thymocytes and placentaltrophoblasts.CD16a is involved in phagocytosis, secretion of enzymes and inflammatory mediators, antibody­dependent cytotoxicity and clearance of immune complexes. Aberrant expression or mutations of CD16a is implicated in susceptibility to recurrent viral infections, systemic lupus erythematosus, and alloimmune neonatal neutropenia.

Source
Human FCGR3A / CD16a (V176) Protein,also called Human FCGR3A / CD16a Protein (176 Val), Gly 17 - Gln 208 (Accession # P08637-1), was produced in human 293 cells (HEK293).
Predicted N-terminus: Gly 17

Molecular Characterization
Human FCGR3A / CD16a (V176) Protein, His Tag is fused with a polyhistidine tag at the C-terminus, and has a calculated MW of 23.7 kDa. The predicted N-terminus is Gly 17. DTT-reduced Protein migrates as 40-50 kDa in SDS-PAGE due to glycosylation.

Endotoxin
Less than 1.0 EU per μg of the Human FCGR3A / CD16a (V176) Protein, His Tag by the LAL method.

Purity
>95% purity as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).

Bioactivity
Immobilized Human HVEM, His Tag (Cat. No. HVM-H52E9) at 5 μg/mL (100 μL/well) can bind Human LIGHT, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. LIT-H5256) with a linear range of 0.3-5 ng/mL (QC tested). Immobilized Human LIGHT, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. LIT-H5256) at 2 μg/mL (100 μL/well) can bind Human DcR3, Fc Tag (Cat. No. TNB-H5255) with a linear range of 0.01-0.3 μg/mL (Routinely tested).

References

(1)Webster NL., et al., 2006, J Leukoc Biol. 79: 294-302.
(2)Nagarajan S., et al., 1995, J Biol Chem. 270: 25762-70.
(3)Ravetch JV., 1989, J. Exp. Med. 170:481.